Continuing strong performance and execution of strategy
Consort Medical plc (LSE: CSRT) (“Consort”, “Consort Medical” or the “Group”), a leading designer and manufacturer of drug delivery device technologies, today announces its audited results for the year ended 30 April 2014.
Jon Glenn, Chief Executive Officer, commented:
“This was an excellent year for Consort Medical with strong performance and execution of strategy, delivering solid organic revenue growth of 5.2% and EPS growth of 8.5% from its diversifying core portfolio. We celebrated a number of ‘firsts’ during the year: the first year Bespak revenues surpassed £100m; the approval and launch of our first auto-injector; the award of our first MHRA commercial drug handling licence; the first development contract award for an innovation centre developed product (NAS030); and the unveiling of the first liquid gas powered auto-injector (Syrina®) and the first dual product injector (Lila®).
“The Board is confident of further future organic growth arising from existing business, from further conversion of the development pipeline programmes and from new opportunities, including the conversion of the innovation pipeline to full development programmes with partners.”
Enquiries:today announces its audited results for the year ended
Consort Medical plc
Tel: +44 (0) 1442 867920
Jonathan Glenn, Chief Executive Officer
Richard Cotton, Chief Financial Officer
Tel: +44 (0) 20 3727 1000
Ben Atwell / Simon Conway